13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001009258
Total reported value
$9.6B
$9.6B
124 檔
22.8%
In Q2 2025, Deerfield Management Company, L.p.'s U.S. equity holdings reached a combined market value of $9.6B, distributed across 124 disclosed stock positions.
Deerfield Management Company, L.p. executed strategic sector rebalancing during Q2 2025, establishing 45 new positions while fully exiting 44 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 24.91% | +1.37% | — | |
| 2 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 4.53% | — | -1.61% | |
| 3 | VTRS | Viatris Inc | Stock-Healthcare | 3.89% | +0.13% | +0.13% | |
| 4 | ✓ | Merus N V | Stock-Other | 3.23% | — | +6.64% | |
| 5 | CNC | Centene CORP | Stock-Healthcare | 3.14% | +0.99% | +19.22% | |
| 6 | IART 0.5 08-15-25Bond | Integra Lifesciences Hld | Bond | 3.14% | — | — | |
| 7 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 3.08% | -0.08% | -7.51% | |
| 8 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 2.83% | — | — | |
| 9 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.82% | -0.62% | +96.43% | |
| 10 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.66% | -0.95% | EXIT | |
| 11 | ALNY 1 09-15-27Bond | Alnylam Pharmaceuticals | Bond | 2.60% | — | — | |
| 12 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.26% | +2.03% | +2.01% | |
| 13 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | Bond | 2.25% | -2.47% | EXIT | |
| 14 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.94% | +0.07% | -1.60% | |
| 15 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.91% | +0.81% | +69.90% | |
| 16 | PFE | Pfizer Inc | Stock-Healthcare | 1.89% | -0.25% | +28.65% | |
| 17 | AHCO | Adapthealth CORP | Stock-Other | 1.70% | -0.36% | +1.99% | |
| 18 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.68% | -0.10% | +24.66% | |
| 19 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.49% | +0.46% | +19.82% | |
| 20 | VERA | Vera Therapeutics Inc | Stock-Other | 1.43% | -0.02% | +218.87% | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 1.28% | — | +52.99% | |
| 22 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.23% | — | — | |
| 23 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.13% | -1.15% | EXIT | |
| 24 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.11% | -0.76% | — | |
| 25 | BAX | Baxter International Inc | Stock-Healthcare | 1.06% | — | — | |
| 26 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.99% | -0.05% | — | |
| 27 | IRON | Disc Medicine Inc | Stock-Other | 0.88% | — | +17.52% | |
| 28 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.86% | -0.06% | — | |
| 29 | EHABUSD | Enhabit Inc | Stock-Other | 0.84% | -0.79% | EXIT | |
| 30 | CERT | Certara Inc | Stock-Other | 0.83% | -0.02% | +94.11% | |
| 31 | NVST | Envista Holdings CORP | Stock-Healthcare | 0.79% | -0.05% | +9.43% | |
| 32 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.76% | -0.12% | -9.59% | |
| 33 | TNDM 1.5 03-15-29 2024Bond | Tandem Diabetes Care Inc | Bond | 0.70% | — | — | |
| 34 | CNMD | Conmed CORP | Stock-Other | 0.66% | — | +14.61% | |
| 35 | PHVS | Pharvaris N.V. | Stock-Other | 0.64% | +0.18% | — | |
| 36 | LNTH 2.625 12-15-27Bond | Lantheus Holdings Inc | Bond | 0.58% | — | — | |
| 37 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.53% | -0.06% | EXIT | |
| 38 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.52% | -0.30% | +10.81% | |
| 39 | PHR | Phreesia Inc | Stock-Other | 0.52% | — | +0.47% | |
| 40 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.52% | -0.55% | EXIT | |
| 41 | MRNA | Moderna Inc | Stock-Healthcare | 0.50% | — | — | |
| 42 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.49% | — | -0.54% | |
| 43 | EMBC | Embecta CORP | Stock-Healthcare | 0.48% | -0.17% | +1.07% | |
| 44 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | Bond | 0.47% | -0.04% | — | |
| 45 | LIVN 2.5 03-15-29Bond | Livanova PLC | Bond | 0.46% | +0.01% | — | |
| 46 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.44% | -0.94% | EXIT | |
| 47 | VTR | Ventas Inc | Stock-Real Estate | 0.41% | — | — | |
| 48 | LQDA | Liquidia CORP | Stock-Other | 0.37% | — | — | |
| 49 | COGT | Cogent Biosciences Inc | Stock-Other | 0.34% | -2.09% | +0.24% | |
| 50 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.33% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OSCR | Oscar Health Inc - Class A | +1.5% | -1.61% | Trim |
| 2 | MRK | Merck & Co. Inc. | +1.2% | NEW | New buy |
| 3 | UTHR | United Therapeutics CORP | +1.1% | +96.43% | Add |
| 4 | VERA | Vera Therapeutics Inc | +0.9% | +218.87% | Add |
| 5 | INDV | Indivior Pharmaceuticals, Inc. | +0.8% | — | Unchanged |
| 6 | LEGN | Legend Biotech Corp-adr | +0.7% | +69.90% | Add |
| 7 | TNDM 1.5 03-15-29 2024Bond | Tandem Diabetes Care Inc | +0.7% | NEW | New buy |
| 8 | ✓ | Merus N V | +0.6% | +6.64% | Add |
| 9 | INSM | Insmed Inc | +0.6% | +52.99% | Add |
| 10 | MRNA | Moderna Inc | +0.5% | NEW | New buy |
| 11 | SPRY | Ars Pharmaceuticals Inc | +0.5% | -7.51% | Trim |
| 12 | LIVN 2.5 03-15-29Bond | Livanova PLC | +0.5% | NEW | New buy |
| 13 | IDYA | Ideaya Biosciences Inc | +0.4% | +19.82% | Add |
| 14 | CERT | Certara Inc | +0.4% | +94.11% | Add |
| 15 | VTR | Ventas Inc | +0.4% | NEW | New buy |
| 16 | INSP | Inspire Medical Systems Inc | +0.3% | NEW | New buy |
| 17 | XENE | Xenon Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 18 | VCYT | Veracyte Inc | +0.3% | NEW | New buy |
| 19 | NEO | Neogenomics Inc | +0.3% | NEW | New buy |
| 20 | TSHA | Taysha Gene Therapies Inc | +0.2% | NEW | New buy |
| 21 | PFE | Pfizer Inc | +0.2% | +28.65% | Add |
| 22 | LRMR | Larimar Therapeutics Inc | +0.2% | — | Unchanged |
| 23 | KYMR | Kymera Therapeutics Inc | +0.2% | +10.12% | Add |
| 24 | OMDA | Omada Health Inc | +0.2% | NEW | New buy |
| 25 | SION | Sionna Therapeutics Inc | +0.2% | +29.93% | Add |
| 26 | IRON | Disc Medicine Inc | +0.1% | +17.52% | Add |
| 27 | ALNY 1 09-15-27Bond | Alnylam Pharmaceuticals | +0.1% | — | Unchanged |
| 28 | NVST | Envista Holdings CORP | +0.1% | +9.43% | Add |
| 29 | JBIO | Jade Biosciences Inc | +0.1% | NEW | New buy |
| 30 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 31 | PRAX | Praxis Precision Medicines I | +0.1% | +10.81% | Add |
| 32 | BBNX | Beta Bionics Inc | +0.1% | +15.00% | Add |
| 33 | FHTX | Foghorn Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | NVCR | NovoCure Limited | 0% | +26.92% | Add |
| 35 | TOI | Oncology Institute Inc/the | 0% | — | Unchanged |
| 36 | COGT | Cogent Biosciences Inc | 0% | +0.24% | Add |
| 37 | MREO | Mereo Biopharma Group Pl-adr | 0% | — | Unchanged |
| 38 | ZBIO | Zenas Biopharma Inc | 0% | — | Unchanged |
| 39 | SYRE | Spyre Therapeutics Inc | 0% | +36.37% | Add |
| 40 | NAMS | NewAmsterdam Pharma Company N.V. | 0% | +24.66% | Add |
| 41 | ✓ | Hillevax Inc | 0% | — | Unchanged |
| 42 | BKD | Brookdale Senior Living Inc | 0% | -1.60% | Trim |
| 43 | PHVS | Pharvaris N.V. | 0% | — | Unchanged |
| 44 | PHR | Phreesia Inc | 0% | +0.47% | Add |
| 45 | RXST | Rxsight Inc | 0% | +126.58% | Add |
| 46 | GPCR | Structure Therapeutics Inc | 0% | — | Unchanged |
| 47 | SHC | Sotera Health Co | 0% | NEW | New buy |
| 48 | COO | Cooper Cos Inc/the | 0% | NEW | New buy |
| 49 | TMO | Thermo Fisher Scientific Inc | 0% | NEW | New buy |
| 50 | UFPT | Ufp Technologies Inc | 0% | NEW | New buy |
According to official SEC Form 13F filings, Deerfield Management Company, L.p. reported a total U.S. public equity portfolio value of $9.6B across 124 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, OSCR, VTRS) accounted for 22.8% of total reported equity market value during Q2 2025.
Top New Position Initiated
MRK
市值: $67.9M
Top Position Liquidated / Trimmed
ACCD 0.5 04-01-26
前期市值: $130.6M
During Q2 2025, Deerfield Management Company, L.p.'s top holdings by market value included NUVL (24.9%)、OSCR (4.5%)、VTRS (3.9%). The largest single position, NUVL, represented 24.9% of total portfolio value.
In Q2 2025, Deerfield Management Company, L.p. made 130 total portfolio adjustments, initiating 45 new buys, adding to 28 positions, trimming 13 holdings, and fully liquidating 44 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.